Analyst firms · Morgan Stanley · VRTX
Morgan Stanley VRTX price target and rating history
Vertex Pharmaceuticals Incorporated (VRTX) · Health Care
Morgan Stanley rates Vertex Pharmaceuticals Incorporated (VRTX) Overweight with a $665 price target, as of its latest action on Sep 2, 2026. It has published 6 rating actions on VRTX since July 2021, including 2 upgrades and 1 downgrade. Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50. Morgan Stanley's $665 is 15% above that.
- Current rating
- Overweight
- Price target
- $665
- Median target, all firms
- $577.50
- Actions on VRTX
- 6
Morgan Stanley price target on VRTX
Every Morgan Stanley rating on VRTX
- Sep 2, 2026
- Dec 3, 2025
- May 3, 2022
- Jan 27, 2022
- Sep 7, 2021
- Jul 30, 2021
How other firms rate VRTX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Outperform | $594 | Sep 21, 2026 |
| Morgan Stanley | Overweight | $665 | Sep 2, 2026 |
| Truist Securities | Buy | $542 | May 27, 2026 |
| Maxim Group | Buy | $575 | Mar 18, 2026 |
| Jefferies | Buy | $580 | Mar 10, 2026 |
| Oppenheimer | Outperform | $600 | Mar 10, 2026 |
| Barclays | Overweight | $606 | Jan 28, 2026 |
| RBC Capital Markets | Outperform | $546 | Jan 22, 2026 |
| Bernstein | Outperform | Jan 12, 2026 | |
| UBS | Buy | $535 | Jan 7, 2026 |
| Wolfe Research | Outperform | $548 | Jan 6, 2026 |
Questions about Morgan Stanley and VRTX
- What is Morgan Stanley's price target for VRTX?
- Morgan Stanley's latest stated price target for Vertex Pharmaceuticals Incorporated (VRTX) is $665, from its action on Sep 2, 2026.
- What is Morgan Stanley's rating on VRTX?
- Morgan Stanley rates VRTX Overweight, a bullish rating, as of Sep 2, 2026.
- When did Morgan Stanley last change its view on VRTX?
- On Sep 2, 2026, Morgan Stanley resumes coverage at Overweight, price target $665.
- How does Morgan Stanley's VRTX target compare with other analysts?
- Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50. Morgan Stanley's $665 is 15% above that.
More VRTX rating histories
- Leerink Partners7
- Maxim Group3
- Jefferies3
- Oppenheimer3
- RBC Capital Markets7
- Bernstein3
- Wolfe Research5
- Raymond James3
- Wells Fargo3
- Canaccord Genuity4
- Piper Sandler3
All Morgan Stanley ratingsVRTX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.